Prognostic effect of programmed cell death ligand 1/programmed cell death 1 expression in cancer stem cells of human oral squamous cell carcinoma

被引:1
|
作者
Todoroki, Keita [1 ,2 ]
Abe, Yushi [1 ,2 ]
Matsuo, Katsuhisa [1 ,2 ]
Nomura, Hidetoshi [1 ]
Kawahara, Akihiko [3 ]
Nakamura, Yoshiaki [4 ]
Nakamura, Moriyoshi [1 ]
Seki, Naoko [1 ]
Kusukawa, Jingo [1 ]
机构
[1] Kurume Univ, Dent & Oral Med Ctr, Sch Med, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan
[2] Kouhoukai Med Corp, Takagi Hosp, Dept Dent & Oral Surg, Okawa, Fukuoka 8310016, Japan
[3] Kurume Univ Hosp, Dept Diagnost Pathol, Kurume, Fukuoka 8300011, Japan
[4] Oita Saiseikai Hita Hosp, Dept Dent & Oral Surg, Hita, Oita 8771292, Japan
关键词
CSC; OSCC; CD44v3; CD24; programmed cell death ligand 1; programmed cell death 1; immune checkpoint inhibitors; HEAD; PD-L1; CD24; IDENTIFICATION; IMMUNOTHERAPY; POPULATION; RECURRENT;
D O I
10.3892/ol.2024.14213
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The relationship between cancer stem cells (CSCs) in oral squamous cell carcinoma (OSCC) and programmed cell death ligand 1 (PD-L1)/programmed cell death 1 (PD-1) remains unclear. Therefore, the present study aimed to clarify the association between the CD44v3(high)/CD24(low) immunophenotype of CSCs in OSCC and PD-L1/PD-1 co-expression, and to assess the prognostic effect of CSCs in terms of immune checkpoint molecules. Formalin-fixed, paraffin-embedded tissue samples and clinicopathological data from 168 patients with OSCC were retrospectively retrieved. Immunohistochemical staining and reverse transcription quantitative polymerase chain reaction were applied to a tissue microarray of the invasive front of each case. Semi-automated cell counting was used to assess CD44v3, CD24, PD-L1 and PD-1 expression by immunohistochemistry (IHC) using a digital image analysis program. Associations between immunological markers and clinicopathological variables were estimated. Patients with the CSC immunophenotype CD44v3(high)/CD24(low), and patients with a high PD-L1/PD-1-positive cell density in the tumor parenchyma and stroma had significantly lower survival rates. Furthermore, patients with the CSC immunophenotype (CD44v3(high)/CD24(low)) and high PD-L1/PD-1 co-expression had even lower survival rates (P<0.01, log-rank test). Notably, there was a positive correlation between CD44v3 and PD-L1 expression (tau=0.1096, P=0.0366, Kendall rank correlation coefficient) and a negative correlation between CD24 and PD-1 expression (tau=-0.1387, P=0.0089, Kendall rank correlation coefficient). Additionally, the high CD44v3 expression group, as determined by IHC, exhibited significantly decreased expression of U2 small nuclear RNA auxiliary factor 1 (U2AF1) at the mRNA level compared with that in the low CD44v3 expression group (P<0.001, Mann-Whitney U test), and U2AF1 and PD-L1 mRNA expression exhibited a significant negative correlation (tau=-0.3948, P<0.001, Kendall rank correlation coefficient). In conclusion, CSCs in OSCC may evade host immune mechanisms and maintain CSC stemness via PD-L1/PD-1 co-expression, resulting in unfavorable clinical outcomes.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] A Comparative Study to Assess the Increased Expression of Programmed Cell Death-1 (PD1) and Programmed Cell Death- Ligand-1 (PDL1) in Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma
    Srivastava, Sonalika
    Sinha, Abhishek
    Srivastava, Sunita
    Mishra, Anuj
    JOURNAL OF INDIAN ACADEMY OF ORAL MEDICINE AND RADIOLOGY, 2023, 35 (04) : 468 - 472
  • [42] Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type
    Jo, Jae-Cheol
    Kim, Misung
    Choi, Yunsuk
    Kim, Hyun-Jung
    Kim, Ji Eun
    Chae, Seoung Wan
    Kim, Hawk
    Cha, Hee Jeong
    ANNALS OF HEMATOLOGY, 2017, 96 (01) : 25 - 31
  • [43] Expression of Programmed Cell Death 1 and Programmed Cell Death Ligand 1 in Extranodal NK/T-Cell Lymphoma, Nasal Type
    Jo, Jae-Cheol
    Choi, Yunsuk
    Cha, Hee Jeong
    Lee, Eun Hee
    Kang, Eun Kyoung
    Kim, Hawk
    BLOOD, 2015, 126 (23)
  • [44] Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma
    Mikami, Shuji
    Mizuno, Ryuichi
    Kondo, Tsunenori
    Shinohara, Nobuo
    Nonomura, Norio
    Ozono, Seiichiro
    Eto, Masatoshi
    Tatsugami, Katsunori
    Takayama, Tatsuya
    Matsuyama, Hideyasu
    Kishida, Takeshi
    Oya, Mototsugu
    CANCER SCIENCE, 2019, 110 (06) : 1820 - 1828
  • [45] Programmed Cell Death-1/Programmed Cell Death-1 Ligand as Prognostic Markers of Coronavirus Disease 2019 Severity
    Niedzwiedzka-Rystwej, Paulina
    Majchrzak, Adam
    Aksak-Was, Bogusz
    Serwin, Karol
    Czajkowski, Zenon
    Grywalska, Ewelina
    Korona-Glowniak, Izabela
    Rolinski, Jacek
    Parczewski, Milosz
    CELLS, 2022, 11 (12)
  • [46] Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type
    Jae-Cheol Jo
    Misung Kim
    Yunsuk Choi
    Hyun-Jung Kim
    Ji Eun Kim
    Seoung Wan Chae
    Hawk Kim
    Hee Jeong Cha
    Annals of Hematology, 2017, 96 : 25 - 31
  • [47] Association of Programmed Death Ligand-1 Overexpression with the Grade and Stage of Oral Squamous Cell Carcinoma
    Qureshi, Zeeshan Mustafa
    Qamar, Samina
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2020, 30 (06): : 662 - 664
  • [48] Programmed-cell death ligand 1 (PD-L1) expression in equine sarcoids and squamous cell carcinoma
    Pimenta, Jose
    Prada, Justina
    Pires, Isabel
    Cotovio, Mario
    OPEN VETERINARY JOURNAL, 2024, 14 (06) : 1476 - 1482
  • [49] Programmed cell death 1 expression in esophageal squamous cell carcinoma and association with clinical characteristics
    Feng, Z.
    Li, Xiang-lei
    Hai-tao, W.
    Zuo-pei, W.
    Bao-li, H.
    Hai-feng, Z.
    Xiao-long, W.
    Li, L.
    INDIAN JOURNAL OF CANCER, 2015, 52 (07) : 176 - 178
  • [50] Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy
    Fang, Xiao-Na
    Fu, Li-Wu
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2016, 11 (02) : 141 - 151